tradingkey.logo
๎™
๎™ผ
tradingkey.logo
๎™

Aspire Biopharma Holdings Inc

ASBP
0.950USD
+0.040+4.38%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
26.72M์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
๎™

Aspire Biopharma Holdings Inc

0.950
+0.040+4.38%

์ž์„ธํ•œ ๋‚ด์šฉ์€ Aspire Biopharma Holdings Inc ํšŒ์‚ฌ

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Inc ์ •๋ณด

๎™Œ
์ข…๋ชฉ ์ฝ”๋“œ ASBP
ํšŒ์‚ฌ ์ด๋ฆ„Aspire Biopharma Holdings Inc
์ƒ์žฅ์ผFeb 18, 2022
CEO- -
์ง์› ์ˆ˜- -
์œ ํ˜•Ordinary Share
ํšŒ๊ณ„ ์—ฐ๋„ ์ข…๋ฃŒFeb 18
์ฃผ์†Œ194 Candelaro Drive, #233
๋„์‹œHUMACAO
์ฆ๊ถŒ ๊ฑฐ๋ž˜์†ŒNASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐ€Puerto Rico
์šฐํŽธ ๋ฒˆํ˜ธ00791
์ „ํ™”
์›น์‚ฌ์ดํŠธ
์ข…๋ชฉ ์ฝ”๋“œ ASBP
์ƒ์žฅ์ผFeb 18, 2022
CEO- -

Aspire Biopharma Holdings Inc์˜ ํšŒ์‚ฌ ์ž„์›์ง„

๎™Œ
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
263.28K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
10.00K
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
์ด๋ฆ„
์ด๋ฆ„/์ง์œ„
์ง์œ„
์ฃผ์‹ ๋ณด์œ 
๋ณ€๋™
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
263.28K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
10.00K
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--

์ˆ˜์ต ๋ถ„์„

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.
์‚ฌ์—…๋ณ„
์ง€์—ญ๋ณ„
๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ฃผ์‹ ๋ณด์œ  ํ†ต๊ณ„

๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Feb 25
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Wed, Feb 25
์ฃผ์ฃผ
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Ardsley Advisory Partners LP
5.35%
Higginson (Kraig)
5.24%
UBS Financial Services, Inc.
1.25%
Friedman (Lance)
1.10%
Ajjarapu (Surendra K)
0.56%
๊ธฐํƒ€
86.50%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น„์œจ
Ardsley Advisory Partners LP
5.35%
Higginson (Kraig)
5.24%
UBS Financial Services, Inc.
1.25%
Friedman (Lance)
1.10%
Ajjarapu (Surendra K)
0.56%
๊ธฐํƒ€
86.50%
์ฃผ์ฃผ ์œ ํ˜•
์ฃผ์ฃผ
๋น„์œจ
Individual Investor
7.47%
Hedge Fund
5.51%
Investment Advisor
2.53%
Research Firm
0.40%
Investment Advisor/Hedge Fund
0.16%
Venture Capital
0.13%
๊ธฐํƒ€
83.79%

๊ธฐ๊ด€ ์ฃผ์‹ ๋ณด์œ 

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Mon, Dec 8
๋ณด๊ณ  ๊ธฐ๊ฐ„
๊ธฐ๊ด€ ์ˆ˜
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
2025Q4
63
3.12M
4.40%
--
2025Q3
65
3.12M
11.03%
+825.14K
2025Q2
62
2.05M
9.35%
+603.03K
2025Q1
98
1.44M
45.11%
-19.31M
2024Q4
95
589.74K
302.57%
-13.72K
2024Q3
102
603.46K
307.62%
-79.18K
2024Q2
105
682.64K
311.95%
-1.09M
2024Q1
104
1.77M
266.21%
-22.17M
2023Q4
100
1.85M
266.31%
-691.34K
2023Q3
98
2.54M
279.18%
-380.89K
๋” ๋ณด๊ธฐ

์ฃผ์ฃผ ํ™œ๋™

๎™Œ
์ด๋ฆ„
๋ณด์œ  ์ฃผ์‹
๋น„์œจ
๋ณ€๋™
Chg %
๋‚ ์งœ
Higginson (Kraig)
10.53M
9.8%
--
--
Dec 01, 2025
Friedman (Lance)
2.21M
2.05%
-1.66M
-42.98%
May 06, 2025
Ajjarapu (Surendra K)
1.12M
1.04%
--
--
Dec 01, 2025
Crewe Advisors LLC
813.43K
0.76%
+186.57K
+29.76%
Sep 30, 2025
Scheidemann (Ernest J. Jr.)
564.17K
0.52%
--
--
Dec 01, 2025
The Vanguard Group, Inc.
428.55K
0.4%
+348.34K
+434.27%
Sep 30, 2025
Doss (Howard A)
400.00K
0.37%
--
--
Dec 01, 2025
๋” ๋ณด๊ธฐ

๊ด€๋ จ ETF

๎™Œ
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: Sat, Dec 6
์ด๋ฆ„
๋น„์œจ
SPAC and New Issue ETF
0%
SPAC and New Issue ETF
๋น„์œจ0%

์ฃผ์‹ ๋ฐฐ๋‹น๊ธˆ

๎™Œ
์ง€๋‚œ 5๋…„ ๋™์•ˆ ์ด 0.00 USD์˜ ๋ฐฐ๋‹น๊ธˆ์ด ๋ถ„๋ฐฐ๋˜์—ˆ์Šต๋‹ˆ๋‹ค.
๋‚ ์งœ
๋ฐฐ๋‹น๊ธˆ
๊ธฐ์ค€์ผ
์ง€๊ธ‰์ผ
๋ฐฐ๋‹น๋ฝ์ผ
๋ฐ์ดํ„ฐ ์—†์Œ

์ฃผ์‹ ๋ถ„ํ• 

๎™Œ
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Jan 14, 2026
Merger
40โ†’1
๋‚ ์งœ
๋ฐฐ๋‹น๋ฝ์ผ
์œ ํ˜•
๋น„์œจ
Jan 14, 2026
Merger
40โ†’1
KeyAI
๎™